BeOne’s Brukinsa hits goal in mantle cell lymphoma confirmatory trial

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new chemotherapy-free standard” in first-line mantle cell lymphoma. | A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a “new chemotherapy-free standard” in first-line mantle cell lymphoma.